{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T10:07:49Z","timestamp":1776247669207,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40261-014-0247-5","type":"journal-article","created":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T15:59:20Z","timestamp":1415980760000},"page":"887-894","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A Phase I Dose-Escalation and Bioequivalence Study of a Trastuzumab Biosimilar in Healthy Male Volunteers"],"prefix":"10.1007","volume":"34","author":[{"given":"Liselijn A. B.","family":"Wisman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard P. M.","family":"De Cock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joannes A. A.","family":"Reijers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid M. C.","family":"Kamerling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra H. G.","family":"Van Os","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke L.","family":"de Kam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacobus","family":"Burggraaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerrit","family":"Voortman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"247_CR1","doi-asserted-by":"crossref","unstructured":"Van Cutsem E, Kang YK, Chung H, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) [abstract no. LBA4509]. J Clin Oncol. 2009;27(18s).","DOI":"10.1200\/jco.2009.27.18s.lba4509"},{"issue":"16","key":"247_CR2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659\u201372.","journal-title":"N Engl J Med"},{"issue":"11","key":"247_CR3","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783\u201392.","journal-title":"N Engl J Med"},{"key":"247_CR4","unstructured":"European Medicines Agency. Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues (EMA\/CHMP\/BMWP\/403543\/2010); 2012. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/06\/WC500128686.pdf ."},{"key":"247_CR5","unstructured":"European Medicines Agency. Guideline on bioanalytical method validation (EMEA\/CHMP\/EWP\/192217\/2009); 2011. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2011\/08\/WC500109686.pdf ."},{"issue":"2","key":"247_CR6","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1177\/0091270012436560","volume":"53","author":"C Wynne","year":"2012","unstructured":"Wynne C, Harvey V, Schwabe C, et al. Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I\/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer. J Clin Pharmacol. 2012;53(2):192\u2013201.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"247_CR7","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","volume":"13","author":"CH Chung","year":"2008","unstructured":"Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13(6):725\u201332.","journal-title":"Oncologist"},{"issue":"Suppl 2","key":"247_CR8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000055403","volume":"61","author":"N Cook-Bruns","year":"2001","unstructured":"Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology. 2001;61(Suppl 2):58\u201366.","journal-title":"Oncology"},{"issue":"3","key":"247_CR9","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1200\/JCO.1996.14.3.737","volume":"14","author":"J Baselga","year":"1996","unstructured":"Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2\/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14(3):737\u201344.","journal-title":"J Clin Oncol"},{"issue":"10","key":"247_CR10","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2005.01.014","volume":"23","author":"J Baselga","year":"2005","unstructured":"Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol. 2005;23(10):2162\u201371.","journal-title":"J Clin Oncol"},{"issue":"5","key":"247_CR11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.2010.12","volume":"87","author":"EC Dijkers","year":"2010","unstructured":"Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87(5):586\u201392.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"247_CR12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-005-1026-z","volume":"56","author":"R Bruno","year":"2005","unstructured":"Bruno R, Washington CB, Lu JF, et al. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol. 2005;56(4):361\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"21","key":"247_CR13","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1200\/JCO.2003.12.109","volume":"21","author":"B Leyland-Jones","year":"2003","unstructured":"Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol. 2003;21(21):3965\u201371.","journal-title":"J Clin Oncol"},{"key":"247_CR14","unstructured":"European Medicines Agency. Guideline on the investigation of bioequivalence (CPMP\/EWP\/QWP\/1401\/98 Rev. 1\/ Corr**). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/01\/WC500070039.pdf . Accessed 3 Nov 2014."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0247-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-014-0247-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-014-0247-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,17]],"date-time":"2019-08-17T07:33:13Z","timestamp":1566027193000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-014-0247-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,7]]},"references-count":14,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["247"],"URL":"https:\/\/doi.org\/10.1007\/s40261-014-0247-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,7]]}}}